0001209191-23-026581.txt : 20230502 0001209191-23-026581.hdr.sgml : 20230502 20230502171018 ACCESSION NUMBER: 0001209191-23-026581 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230428 FILED AS OF DATE: 20230502 DATE AS OF CHANGE: 20230502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tak Paul Peter CENTRAL INDEX KEY: 0001873905 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40629 FILM NUMBER: 23880347 MAIL ADDRESS: STREET 1: CANDEL THERAPEUTICS, INC. STREET 2: 117 KENDRICK ST SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Candel Therapeutics, Inc. CENTRAL INDEX KEY: 0001841387 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 522214851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 617-916-5445 MAIL ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 FORMER COMPANY: FORMER CONFORMED NAME: Candel Therapeutics, Inic. DATE OF NAME CHANGE: 20210120 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-28 0 0001841387 Candel Therapeutics, Inc. CADL 0001873905 Tak Paul Peter C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450 NEEDHAM MA 02494 1 1 0 0 Chief Executive Officer 0 Stock Option (Right to Buy) 1.29 2023-04-28 4 A 0 180000 0.00 A 2033-04-28 Common Stock 180000 180000 D One third of the shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. One third of the shares underlying this option shall vest and become exercisable if the average closing market price of the Issuer's common stock exceeds $3.00 per share for at least 20 consecutive trading days prior to the expiration of the option. The final third of shares underlying this option shall vest and become exercisable if the average closing market price of the Issuer's common stock exceeds $4.50 per share for at least 20 consecutive trading days prior to the expiration of the option. If either stock price hurdle is achieved prior to April 28, 2024, the applicable award would vest fully on April 28, 2024, so long as the Reporting Person remains an employee or service provider of the Issuer through such date. /s/ Jason A. Amello as Attorney-In-Fact for Paul Peter Tak 2023-05-02